These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 18854347)

  • 21. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis.
    Cui Y; Xiao Z; Shuxia W; Zhenjun Z; Hengguo Z; Liangyi F; Weicheng G; Li L; Guangfeng Z; Yunzhen S; Guangfu D
    Scand J Rheumatol; 2010 May; 39(3):229-32. PubMed ID: 20109079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH; Stone M; Payne U; Zhang X; Ionescu M; Lobanok T; King L; Poole AR; Inman RD
    Arthritis Rheum; 2005 Mar; 52(3):885-91. PubMed ID: 15751093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis.
    Pang L; Wang L; Suo T; Hao H; Fang X; Jia J; Huang F; Tang J
    J Rheumatol; 2008 Nov; 35(11):2220-8. PubMed ID: 19004053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY
    J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
    Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
    Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
    Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
    J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.
    Arends S; van der Veer E; Groen H; Houtman PM; Jansen TL; Leijsma MK; Bijzet J; Limburg PC; Kallenberg CG; Spoorenberg A; Brouwer E
    J Rheumatol; 2011 Aug; 38(8):1644-50. PubMed ID: 21632677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
    Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S
    Platelets; 2010; 21(2):126-31. PubMed ID: 20050759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
    Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis.
    Vazquez-Del Mercado M; Garcia-Gonzalez A; Muñoz-Valle JF; Garcia-Iglesias T; Martinez-Bonilla G; Bernard-Medina G; Sanchez-Ortiz A; Ornelas-Aguirre JM; Salazar-Paramo M; Gamez-Nava JI; Gonzalez-Lopez L
    J Rheumatol; 2002 Mar; 29(3):522-6. PubMed ID: 11908566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteopontin expression in oral lichen planus.
    Zhou ZT; Wei BJ; Shi P
    J Oral Pathol Med; 2008 Feb; 37(2):94-8. PubMed ID: 18197854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension.
    Irita J; Okura T; Manabe S; Kurata M; Miyoshi K; Watanabe S; Fukuoka T; Higaki J
    Am J Hypertens; 2006 Mar; 19(3):293-7. PubMed ID: 16500516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.